当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Abstract：

:This study describes the inhibitory effect of 5 alpha-dihydrotestosterone (5 alpha-DHT) and its precursors testosterone (T) and androst-4-ene-3,17-dione (delta 4-DIONE) on the growth of the estrogen-sensitive human breast cancer cell line ZR-75-1. In the absence of estrogens, cell proliferation measured after a 12-day incubation period was 50-60% inhibited by maximal concentrations of 5 alpha-DHT, T, or delta 4-DIONE with half-maximal effects (IC50 values) observed at 0.10, 0.15 and 15 nM, respectively. This growth inhibition by androgens was due to an increase in generation time and a lowering of the saturation density of cell cultures. The antiestrogen LY156758 (300 nM) induced 25-30% inhibition of basal cell growth, its effect being additive to that of 5 alpha-DHT. The mitogenic effect of 1 nM estradiol (E2) was completely inhibited by increasing concentrations of 5 alpha-DHT with a potency (IC50 = 0.10 nM) similar to that measured when the androgen was used alone. E2 had a more rapid effect on cell proliferation than 5 alpha-DHT, the latter requiring at least 5 to 6 days to exert significant growth inhibition. As found in the absence of estrogens, maximal inhibition of cell proliferation in the presence of E2 was achieved by the combination of the antiestrogen and 5 alpha-DHT. Supraphysiological concentrations of E2 (up to 1 microM) were needed to completely reverse the growth inhibitory effect of a submaximal concentration of 5 alpha-DHT (1 nM). The antiproliferative effect of androgens was competitively reversed by the antiandrogen hydroxyflutamide, thus indicating an androgen receptor-mediated mechanism. The present data suggest the potential benefits of an androgen-antiestrogen combination therapy in the endocrine management of breast cancer.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Poulin R,Baker D,Labrie F

doi

10.1007/BF01805942

subject

Has Abstract

pub_date

1988-10-01 00:00:00

pages

213-25

issue

2

eissn

0167-6806

issn

1573-7217

journal_volume

12

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Adjuvant dietary fat intake reduction in postmenopausal breast cancer patient management. The Women's Intervention Nutrition Study (WINS).

    abstract：:Management of localized breast cancer now commonly involves a breast-sparing approach combined with systemic adjuvant therapy resulting in improved cosmetic results and patient survival. Reducing dietary fat intake represents a conceptually new approach to further improve outcome of patients with resected breast cance...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01834637

    authors： Chlebowski RT,Rose D,Buzzard IM,Blackburn GL,Insull W Jr,Grosvenor M,Elashoff R,Wynder EL

    更新日期：1992-01-01 00:00:00

  • Height, weight, and risk of breast cancer relapse.

    abstract：:The records of 231 patients with primary breast cancer and 85 patients with metastatic breast cancer were reviewed to determine whether indices of body weight were associated with prognosis. Results support previous reports that indices of body weight are relatively weak, but real, prognostic factors. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01807654

    authors： Eberlein T,Simon R,Fisher S,Lippman ME

    更新日期：1985-01-01 00:00:00

  • Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients.

    abstract：PURPOSE:This study aimed to identify and classify genetic variants in consensus moderate-to-high-risk predisposition genes associated with Hereditary Breast and Ovarian Cancer Syndrome (HBOC), in BRCA1/2-negative patients from Brazil. METHODS:The study comprised 126 index patients who met NCCN clinical criteria and te...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05985-9

    authors： Gomes R,Spinola PDS,Brant AC,Matta BP,Nascimento CM,de Aquino Paes SM,Bonvicino CR,Dos Santos ACE,Moreira MAM

    更新日期：2020-10-30 00:00:00

  • Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.

    abstract：PURPOSE:To investigate whether fertility preservation (FP) in adult women diagnosed with breast cancer (BC) may impact the time interval between diagnosis and start of chemotherapy in an adjuvant or neo-adjuvant setting. METHODS:Retrospective cohort study of breast cancer patients diagnosed between January 2012 and De...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05858-1

    authors： D'Hondt C,Vanhoeij M,Van Moer E,Segers I,Fontaine C,Tournaye H,De Vos M

    更新日期：2020-11-01 00:00:00

  • Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

    abstract：:We have measured the levels of tamoxifen and three of its metabolites in the blood of patients receiving tamoxifen alone or combination therapy with tamoxifen and medroxyprogesterone acetate. Our results indicate that addition of the progestogen significantly alters the metabolism of tamoxifen over a six-month period....

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/BF01833345

    authors： Reid AD,Horobin JM,Newman EL,Preece PE

    更新日期：1992-01-01 00:00:00

  • Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population.

    abstract：BACKGROUND:Estimating an individual woman's absolute risk for breast cancer is essential for decision making about screening and preventive recommendations. Although the current standard, the Gail model, is well calibrated in populations, it performs poorly for individuals. Mammographic breast density (BD) may improve ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-5152-4

    authors： Tice JA,Cummings SR,Ziv E,Kerlikowske K

    更新日期：2005-11-01 00:00:00

  • Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.

    abstract：:Clinical practice guidelines recommend yearly surveillance mammography for breast cancer survivors, yet many women do not receive this service. The objective of this study was to evaluate factors related to long-term surveillance mammography adherence among breast cancer survivors. We conducted a retrospective cohort ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2816-3

    authors： Wirtz HS,Boudreau DM,Gralow JR,Barlow WE,Gray S,Bowles EJ,Buist DS

    更新日期：2014-02-01 00:00:00

  • Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.

    abstract：:To investigate the prognostic value of tumor markers, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) levels at diagnosis of systemic recurrence. After primary treatments of locoregional breast cancers, serum CA 15-3 and/or CEA concentrations were regularly measured, and systemic recurrences were iden...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2695-7

    authors： Lee JS,Park S,Park JM,Cho JH,Kim SI,Park BW

    更新日期：2013-10-01 00:00:00

  • Biological and clinical significance of PARP1 protein expression in breast cancer.

    abstract：:Poly(ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair. PARP inhibitors have gained recent attention as promising therapeutic agents for the treatment of solid tumours including breast cancer (BC). However, the biological and clinical significance of PARP1 expression in BC and its role in DNA-damage ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3230-1

    authors： Green AR,Caracappa D,Benhasouna AA,Alshareeda A,Nolan CC,Macmillan RD,Madhusudan S,Ellis IO,Rakha EA

    更新日期：2015-01-01 00:00:00

  • Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.

    abstract：PURPOSE:Platinum plays an important role in the treatment of triple-negative breast cancer (TNBC) in neoadjuvant and metastatic settings. However, its role in an adjuvant setting remains unclear. METHODS:In this non-inferior randomized phase 2 trial, we randomly assigned 308 chemotherapy-naive patients with histologic...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-020-05648-9

    authors： Du F,Wang W,Wang Y,Li M,Zhu A,Wang J,Cai R,Ma F,Fan Y,Li Q,Zhang P,Todorovic V,Yuan P,Xu B

    更新日期：2020-07-01 00:00:00

  • Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

    abstract：PURPOSE:The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality of life after the end of chemotherapy. METHODS:We included 135 newly diagn...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4720-3

    authors： de Vries YC,Boesveldt S,Kelfkens CS,Posthuma EE,van den Berg MMGA,de Kruif JTCM,Haringhuizen A,Sommeijer DW,Buist N,Grosfeld S,de Graaf C,van Laarhoven HWM,Kampman E,Winkels RM

    更新日期：2018-07-01 00:00:00

  • Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.

    abstract：:Targeting HER-2 over-expressing breast cancer cells with trastuzumab has resulted in significant improvements in both disease-free and overall survival rates. However, despite a favorable initial response, some cancer cells become resistant and develop into fatal metastatic disease. Here we report that we can specific...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0828-9

    authors： Zhang KX,Kim C,Chow E,Chen IS,Jia W,Rennie PS

    更新日期：2011-01-01 00:00:00

  • Assessment of an APOBEC3B truncating mutation, c.783delG, in patients with breast cancer.

    abstract：PURPOSE:APOBEC3B belongs to the family of DNA-editing enzymes. A copy number variant targeting the genomic APOBEC3A-APOBEC3B locus has a significant impact on breast cancer risk, but the relative contribution of APOBEC3B is uncertain. In this study, we investigate a loss-of-function mutation that selectively targets AP...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-016-4100-9

    authors： Radmanesh H,Spethmann T,Enßen J,Schürmann P,Bhuju S,Geffers R,Antonenkova N,Khusnutdinova E,Sadr-Nabavi A,Shandiz FH,Park-Simon TW,Hillemanns P,Christiansen H,Bogdanova N,Dörk T

    更新日期：2017-02-01 00:00:00

  • Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.

    abstract：:Previous studies showing the presence of antibodies against tumor-associated antigens in healthy individuals suggest that antibody-dependent cell cytotoxicity (ADCC) might play a role in the development of breast cancer. We hypothesized that functional polymorphisms in fragment c gamma receptor (FcgR) genes were assoc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1109-3

    authors： Iwasaki M,Shimada N,Kasuga Y,Yokoyama S,Onuma H,Nishimura H,Kusama R,Hamada GS,Nishimoto IN,Iyeyasu H,Motola J Jr,Laginha FM,Anzai R,Tsugane S

    更新日期：2011-04-01 00:00:00

  • Quality of life in women with recurrent breast cancer.

    abstract：:Although the psychosocial concomitants of early-stage breast cancer have been well-documented, the relationship between cancer recurrence and quality of life remains less clear. We conducted a prospective, longitudinal study in order to clarify the relationship between recurrent cancer and quality of life, and to dete...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006172024218

    authors： Bull AA,Meyerowitz BE,Hart S,Mosconi P,Apolone G,Liberati A

    更新日期：1999-03-01 00:00:00

  • Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo.

    abstract：:The glycolytic phenotype is a widespread phenomenon in solid cancer forms, including breast cancer. Dichloroacetate (DCA) has recently been proposed as a novel and relatively non-toxic anti-cancer agent that can reverse the glycolytic phenotype in cancer cells through the inhibition of pyruvate dehydrogenase kinase. W...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-009-0435-9

    authors： Sun RC,Fadia M,Dahlstrom JE,Parish CR,Board PG,Blackburn AC

    更新日期：2010-02-01 00:00:00

  • Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.

    abstract：:From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin. Patients were eligible if they had progressive disease after either adjuvant (2 patients) or previous chemoth...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01806146

    authors： Colozza M,Gori S,Mosconi AM,Anastasi P,Basurto C,Ludovini V,De Angelis V,Giansanti M,Tonato M

    更新日期：1996-01-01 00:00:00

  • Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.

    abstract：:Metastasis to the regional lymph nodes through the lymphatic vessels is a common step in the progression of cancer and an important prognostic factor in many types of cancer. Recent evidence suggests that VEGF-C promotes lymphangiogenesis, and that tumor lymphangiogenesis in turn promotes lymphatic metastasis. We have...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-5783-x

    authors： Nakamura Y,Yasuoka H,Tsujimoto M,Imabun S,Nakahara M,Nakao K,Nakamura M,Mori I,Kakudo K

    更新日期：2005-05-01 00:00:00

  • GSTT1 and GSTP1 polymorphisms and breast cancer risk: a meta-analysis.

    abstract：:Cytosolic glutathione S-transferase comprises multiple isoenzymes; studies have principally examined mu-1 (GSTM1: null/present), theta-1 (GSTT1: null/present) and pi-1 (GSTP1 Ile105Val) gene polymorphisms concerning breast cancer risk. Regarding GSTT1 and GSTP1 polymorphisms, studies remain controversial and no recent...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-009-0520-0

    authors： Sergentanis TN,Economopoulos KP

    更新日期：2010-05-01 00:00:00

  • Flexible covariate effects in the proportional hazards model.

    abstract：:The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01840837

    authors： Hastie T,Sleeper L,Tibshirani R

    更新日期：1992-01-01 00:00:00

  • Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.

    abstract：PURPOSE:The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05728-w

    authors： Xu B,Li W,Zhang Q,Shao Z,Li Q,Wang X,Li H,Sun T,Yin Y,Zheng H,Feng J,Zhang H,Lei G,Restuccia E

    更新日期：2020-08-01 00:00:00

  • A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

    abstract：:To determine whether capecitabine schedule adaptation improves the tolerability of capecitabine-paclitaxel combination therapy for metastatic breast cancer (MBC), patients with anthracycline-pretreated HER2-negative MBC were randomized to either arm A (21-day cycles: capecitabine 1,000 mg/m(2) twice daily, days 1-14; ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1776-8

    authors： Lortholary A,Hardy-Bessard AC,Bachelot T,de Rauglaudre G,Alexandre J,Bourgeois H,Jaubert D,Paraiso D,Largillier R

    更新日期：2012-01-01 00:00:00

  • A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.

    abstract：:A risk prediction model is a statistical tool for estimating the probability that a currently healthy individual with specific risk factors will develop a condition in the future such as breast cancer. Reliably accurate prediction models can inform future disease burdens, health policies and individual decisions. Brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-011-1818-2

    authors： Meads C,Ahmed I,Riley RD

    更新日期：2012-04-01 00:00:00

  • Availability of prior mammograms affects incomplete report rates in mobile screening mammography.

    abstract：PURPOSE:Mobile mammography can improve access to screening mammography in rural areas and underserved populations. We evaluated the frequency of incomplete reports in mobile mammography screening and the relationships between prior mammograms and recall rates. METHODS:The frequency of incomplete mammogram reports, the...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4861-4

    authors： Roubidoux MA,Shih-Pei Wu P,Nolte ELR,Begay JA,Joe AI

    更新日期：2018-10-01 00:00:00

  • Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.

    abstract：:IBEP-2, an established cell line recently derived from breast carcinoma, was characterized with regard to estrogen receptor (ER) expression, cell mitogenic response to estrogenic stimulation and sensitivity to antiestrogens. In addition, we examined ER modulation following binding of agonist and antagonists, and the E...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/B:BREA.0000032922.87541.31

    authors： Journé F,Body JJ,Leclercq G,Nonclercq D,Laurent G

    更新日期：2004-07-01 00:00:00

  • High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.

    abstract：:The purpose of the study was to compare breast-conserving therapy (BCT) and mastectomy (M) in BRCA1/2 mutation carriers. Women with invasive breast cancer and a pathogenic mutation in BRCA1 or BRCA2 were included in the study (n = 162). Patients treated with BCT (n = 45) were compared with patients treated with M (n =...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3115-3

    authors： Nilsson MP,Hartman L,Kristoffersson U,Johannsson OT,Borg A,Henriksson K,Lanke E,Olsson H,Loman N

    更新日期：2014-10-01 00:00:00

  • Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.

    abstract：:Toremifene is a triphenylethylene derivative structurally and pharmacologically similar to tamoxifen. This Phase I trial assessed the safety, pharmacokinetics, anti-estrogenic, and estrogenic effects of toremifene at six dose levels (10, 20, 40, 60, 200, and 400 mg/day). The most common side-effects associated with th...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1007/BF01807140

    authors： Kohler PC,Hamm JT,Wiebe VJ,DeGregorio MW,Shemano I,Tormey DC

    更新日期：1990-08-01 00:00:00

  • Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review.

    abstract：PURPOSE:Breast cancer is the most common cancer and leading cause of cancer death in women. Body composition parameters, especially those related to muscle, have become a growing focus of cancer research. In this review, we summarize the literature on breast cancer and muscle parameters as well as combine their outcome...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-019-05352-3

    authors： Aleixo GFP,Williams GR,Nyrop KA,Muss HB,Shachar SS

    更新日期：2019-10-01 00:00:00

  • Followup after 11 years--update of mortality results in the Stockholm mammographic screening trial.

    abstract：:Results from several randomised mammography screening trials have shown that it is possible to reduce mortality in breast cancer by mammographic screening at least for women above 50 years of age. The purpose of this article is to present data on mortality in breast cancer in study and control groups of the Stockholm ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1005872617944

    authors： Frisell J,Lidbrink E,Hellström L,Rutqvist LE

    更新日期：1997-09-01 00:00:00

  • Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

    abstract：:Erratum to: Breast Cancer Res Treat (2013),138:369–381,DOI 10.1007/s10549-012-2389-6. In the original publication of the article, the Fig. 4c and d were published erroneously. The revised Fig. 4 is given in this erratum. ...

    journal_title：Breast cancer research and treatment

    pub_type： 已发布勘误

    doi：10.1007/s10549-016-3752-9

    authors： Wander SA,Zhao D,Besser AH,Hong F,Wei J,Ince TA,Milikowski C,Bishopric NH,Minn AJ,Creighton CJ,Slingerland JM

    更新日期：2016-04-01 00:00:00